BR0012082A - Formulação farmacêutica para administração compreendendo morfina e seu uso - Google Patents
Formulação farmacêutica para administração compreendendo morfina e seu usoInfo
- Publication number
- BR0012082A BR0012082A BR0012082-0A BR0012082A BR0012082A BR 0012082 A BR0012082 A BR 0012082A BR 0012082 A BR0012082 A BR 0012082A BR 0012082 A BR0012082 A BR 0012082A
- Authority
- BR
- Brazil
- Prior art keywords
- morphine
- pharmaceutical formulation
- administration
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title abstract 10
- 229960005181 morphine Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Abstract
"FORMULAçãO FARMACêUTICA PARA ADMINISTRAçãO COMPREENDENDO MORFINA E SEU USO". A presente invenção refere-se a uma formulação farmacêutica para administração intranasal compreendendo morfina ou seu sal farmaceuticamente aceitável a um pH de cerca de 3,0 a cerca de 7,0. Tais formulações provêem absorção aumentada de morfina ou de seu sal farmaceuticamente aceitável. Numa concretização, a presente invenção provê um método para provocar uma resposta analgésica ou anestésica num mamífero que inclui administrar nasalmente uma quantidade terapeuticamente eficaz de morfina ou de seu sal farmaceuticamente aceitável a um pH de cerca de 3,0 a cerca de 7,0.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33453799A | 1999-06-16 | 1999-06-16 | |
PCT/US2000/014157 WO2000076506A1 (en) | 1999-06-16 | 2000-05-23 | Pharmaceutical formulations and methods comprising intranasal morphine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0012082A true BR0012082A (pt) | 2002-05-07 |
Family
ID=23307687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0012082-0A BR0012082A (pt) | 1999-06-16 | 2000-05-23 | Formulação farmacêutica para administração compreendendo morfina e seu uso |
Country Status (30)
Country | Link |
---|---|
US (1) | US6677346B1 (pt) |
EP (2) | EP1183027A4 (pt) |
JP (1) | JP2003501467A (pt) |
KR (1) | KR20020016831A (pt) |
AU (1) | AU774175B2 (pt) |
BG (1) | BG106221A (pt) |
BR (1) | BR0012082A (pt) |
CA (1) | CA2374877C (pt) |
CZ (1) | CZ20014399A3 (pt) |
DE (1) | DE10084709T1 (pt) |
DK (1) | DK200101859A (pt) |
EE (1) | EE200100677A (pt) |
ES (1) | ES2197792B1 (pt) |
FI (1) | FI20012462A (pt) |
GB (1) | GB2367005A (pt) |
HR (1) | HRP20010926A2 (pt) |
HU (1) | HUP0201856A3 (pt) |
IS (1) | IS6202A (pt) |
LT (1) | LT4976B (pt) |
LU (1) | LU90859B1 (pt) |
LV (1) | LV12859B (pt) |
MX (1) | MXPA01012879A (pt) |
NO (1) | NO20015931L (pt) |
NZ (1) | NZ515783A (pt) |
PL (1) | PL352556A1 (pt) |
SE (1) | SE0104203L (pt) |
SI (1) | SI20850A (pt) |
SK (1) | SK18172001A3 (pt) |
TR (1) | TR200103613T2 (pt) |
WO (1) | WO2000076506A1 (pt) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9924797D0 (en) | 1999-10-20 | 1999-12-22 | West Pharm Serv Drug Res Ltd | Compound |
US20040115133A1 (en) * | 2000-05-10 | 2004-06-17 | Wermeling Daniel P. | Intranasal opioid compositions |
US20060083691A1 (en) * | 2000-05-10 | 2006-04-20 | Wermeling Daniel P | Intranasal opioid compositions, delivery devices and methods of using same |
US6572849B2 (en) * | 2000-09-20 | 2003-06-03 | Lee Shahinian, Jr. | Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications |
AU2002303148A1 (en) * | 2001-06-29 | 2003-03-03 | Leon J. Lewandowski | Individualized addiction cessation therapy |
GB0210264D0 (en) * | 2002-05-03 | 2002-06-12 | Arakis Ltd | The treatment of pain and migraine headache |
US20040102476A1 (en) * | 2002-11-25 | 2004-05-27 | Chan Tai Wah | High concentration formulations of opioids and opioid derivatives |
US20050175679A1 (en) * | 2004-02-10 | 2005-08-11 | Michael Moshman | Controlled release formulations |
US20140162965A1 (en) | 2004-08-25 | 2014-06-12 | Aegis Therapeutics, Inc. | Compositions for oral drug administration |
US9895444B2 (en) | 2004-08-25 | 2018-02-20 | Aegis Therapeutics, Llc | Compositions for drug administration |
SI2486942T1 (sl) | 2004-11-24 | 2019-03-29 | Meda Pharmaceuticals Inc. | Sestavki, ki obsegajo azelastin, in postopki za njihovo uporabo |
US9415034B2 (en) * | 2005-01-05 | 2016-08-16 | National Defense Medical Center | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
ES2277743B2 (es) | 2005-06-02 | 2008-12-16 | Universidade De Santiago De Compostela | Nanoparticulas que comprenden quitosano y ciclodextrina. |
JP5276982B2 (ja) * | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
US20070212307A1 (en) * | 2006-02-10 | 2007-09-13 | Daniel Wermeling | Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same |
US8226949B2 (en) | 2006-06-23 | 2012-07-24 | Aegis Therapeutics Llc | Stabilizing alkylglycoside compositions and methods thereof |
CA2667072C (en) * | 2006-12-22 | 2015-11-24 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
GB2477545B (en) * | 2010-02-05 | 2011-12-21 | Special Products Ltd | A liquid morphine composition for buccal administration |
ES2661838T5 (es) | 2011-05-13 | 2021-11-18 | Euro Celtique Sa | Formas de dosificación farmacéuticas intranasales que comprenden naloxona |
US20150231130A1 (en) | 2012-07-26 | 2015-08-20 | Wockhardt Limited | Pharmaceutical composition comprising diamorphine for intranasal administration |
WO2015095389A1 (en) * | 2013-12-18 | 2015-06-25 | Aegis Therapeutics, Llc | Compositions for drug administration |
EP3242676B1 (en) | 2015-01-07 | 2023-10-04 | Tonix Pharmaceuticals Holding Corp. | Magnesium-containing oxytocin formulations and methods of use |
WO2018075979A1 (en) * | 2016-10-21 | 2018-04-26 | Somniferum Labs LLC | Compositions, methods and kits for the safe inhaled delivery of targeted opioids for the treatment of pain and addiction |
JP7378391B2 (ja) * | 2017-10-20 | 2023-11-13 | シエシー ファルマセウティチィ ソシエタ ペル アチオニ | 有効成分としてオピオイド受容体アゴニストを含む医薬製剤、その製造方法および治療的使用 |
JP6941224B2 (ja) | 2018-02-06 | 2021-09-29 | イージス セラピューティクス,エルエルシー | 疾患の処置のための鼻腔内エピネフリン製剤及び方法 |
CN115804754A (zh) * | 2022-12-16 | 2023-03-17 | 广州新济药业科技有限公司 | ***鼻喷剂及其制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4464378A (en) | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4464376A (en) | 1982-07-22 | 1984-08-07 | Richardson-Vicks, Inc. | Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same |
GB8514665D0 (en) * | 1985-06-11 | 1985-07-10 | Eroceltique Sa | Oral pharmaceutical composition |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
GB9202464D0 (en) * | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
DE69434304T2 (de) * | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin |
GB9426102D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Pharmacuetical compositions |
EP1006969A1 (en) * | 1996-09-27 | 2000-06-14 | Nastech Pharmaceutical Co. | Intranasal formulations for promoting sleep and method of using the same |
-
2000
- 2000-05-23 CA CA002374877A patent/CA2374877C/en not_active Expired - Fee Related
- 2000-05-23 WO PCT/US2000/014157 patent/WO2000076506A1/en not_active Application Discontinuation
- 2000-05-23 DE DE10084709T patent/DE10084709T1/de not_active Ceased
- 2000-05-23 NZ NZ515783A patent/NZ515783A/en unknown
- 2000-05-23 SK SK1817-2001A patent/SK18172001A3/sk unknown
- 2000-05-23 HU HU0201856A patent/HUP0201856A3/hu unknown
- 2000-05-23 CZ CZ20014399A patent/CZ20014399A3/cs unknown
- 2000-05-23 EP EP00936212A patent/EP1183027A4/en not_active Withdrawn
- 2000-05-23 EE EEP200100677A patent/EE200100677A/xx unknown
- 2000-05-23 MX MXPA01012879A patent/MXPA01012879A/es unknown
- 2000-05-23 JP JP2001502839A patent/JP2003501467A/ja active Pending
- 2000-05-23 PL PL00352556A patent/PL352556A1/xx not_active Application Discontinuation
- 2000-05-23 KR KR1020017016009A patent/KR20020016831A/ko not_active Application Discontinuation
- 2000-05-23 TR TR2001/03613T patent/TR200103613T2/xx unknown
- 2000-05-23 GB GB0128383A patent/GB2367005A/en not_active Withdrawn
- 2000-05-23 ES ES200150086A patent/ES2197792B1/es not_active Expired - Lifetime
- 2000-05-23 EP EP04001252A patent/EP1419774A1/en not_active Withdrawn
- 2000-05-23 SI SI200020030A patent/SI20850A/sl not_active IP Right Cessation
- 2000-05-23 BR BR0012082-0A patent/BR0012082A/pt not_active IP Right Cessation
- 2000-05-23 AU AU51561/00A patent/AU774175B2/en not_active Ceased
- 2000-06-15 US US09/594,916 patent/US6677346B1/en not_active Expired - Fee Related
-
2001
- 2001-12-04 NO NO20015931A patent/NO20015931L/no not_active Application Discontinuation
- 2001-12-12 DK DK200101859A patent/DK200101859A/da not_active Application Discontinuation
- 2001-12-13 FI FI20012462A patent/FI20012462A/fi not_active IP Right Cessation
- 2001-12-13 HR HR20010926A patent/HRP20010926A2/hr not_active Application Discontinuation
- 2001-12-13 LT LT2001119A patent/LT4976B/lt not_active IP Right Cessation
- 2001-12-13 LU LU90859A patent/LU90859B1/en active
- 2001-12-14 BG BG106221A patent/BG106221A/xx unknown
- 2001-12-14 SE SE0104203A patent/SE0104203L/ not_active Application Discontinuation
- 2001-12-14 IS IS6202A patent/IS6202A/is unknown
-
2002
- 2002-01-18 LV LVP-01-169A patent/LV12859B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0012082A (pt) | Formulação farmacêutica para administração compreendendo morfina e seu uso | |
BR0107869A (pt) | Composições farmacêuticas eletrogiradas | |
BRPI0415007A (pt) | método para tratar, prevenir, modificar ou administrar dor, e, composição farmacêutica | |
BR9406363A (pt) | Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
NZ508526A (en) | Opioid formulations for treating pain | |
ITRM910922A1 (it) | Composizione farmaceutica anticefalalgica per somministrazione endonasale, procedimento per prepararla e suo impiego terapeutico | |
PT814796E (pt) | Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal | |
BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
ES2139132T3 (es) | Composiciones farmaceuticas activas en la terapia de desordenes del sueño. | |
BR0108584A (pt) | Formulações contendo um fármaco anticolinérgico para o tratamento da broncopneumopatia crÈnica obtrutiva | |
BR0316948A (pt) | Composto, formulação farmacêutica, e, uso de um composto | |
ID29530A (id) | Sediaan obat-obatan untuk penggunaan eksternal menggunakan zat-zat non-steroid anti-peradangan dan analgesik | |
SE9601528D0 (sv) | Transdermally administered dextromethorphan as antitissue agent | |
BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
BR0207866A (pt) | Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna | |
AR036321A1 (es) | Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia. | |
DE59914183D1 (de) | Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz | |
EP0799618A3 (en) | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer | |
BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
BR0011880A (pt) | Método para o tratamento de condições co-mórbidas associadas com obesidade, composto, produto, uso de um composto, e, composição farmacêutica | |
BRPI0408113A (pt) | métodos para tratar ou prevenir um distúrbio do sistema nervoso central, para controlar um distúrbio do sistema nervoso central e para reduzir ou evitar um efeito adverso associado com a administração de um ingrediente ativo secundário em um paciente que sofre de um distúrbio do sistema nervoso central, e, composição farmacêutica | |
BR9910201A (pt) | Sistema terapêutico transdérmico para emprego de candesartan | |
EE04095B1 (et) | Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks | |
BR9809457A (pt) | Sais de peptìdeo de bpc com atividade organo-protetora, o processo para sua preparação e seu uso em terapia. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADE |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |